Lack of association of IL-6 (-174 G>C) and TNF-α (-238 G>A) variants with paranoid schizophrenia in Indian Bengalee population

Cytokine

Volumn 61, Issue 2, 2013, Pages 455-458

  Debnath, Monojit ^a   Mitra, Bikash ^b,d   Bera, Nirmal Kumar ^c   Chaudhuri, Tapas Kumar ^b   Zhang, Ya ping ^a,d  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF NORTH BENGAL   (India)

^c NORTH BENGAL MEDICAL COLLEGE   (India)

^d YUNNAN UNIVERSITY   (China)

Author keywords

IL 6; Inflammation; Paranoid schizophrenia; TNF

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IL 6 GENE; INDIA; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TNF ALPHA GENE;

CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; INTERLEUKIN-6; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA, PARANOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873162927     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.10.028     Document Type: Article

References (55)

1. Owen M.J., Craddock N., O'Donovan M.C. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiat 2010, 67:667-673.
2. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
3. Muller N., Schwarz M. The role of immune system in schizophrenia. Curr Immunol Rev 2010, 6:213-220.
4. Potvin S., Stip E., Sepehry A.A., et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiat 2008, 63:801-808.
5. Li Q., Cheung C., Wei R., et al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One 2009, 4(7):e6354.
6. Muller N., Wagner J.K., Krause D., et al. Impaired monocyte activation in schizophrenia. Psychiat Res 2012, 198:341-346.
7. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiat Res 2005, 39:311-323.
8. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiat 2010, 167:261-280.
9. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiat, in press.
10. Gilmore J.H., Fredrik Jarskog L., et al. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNF alpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29:1221-1229.
11. Smith S.E., Li J., Gabett K., et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
12. Ellman L.M., Deicken R.F., Vinogradov S., et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010, 121:46-54.
13. Dalman C., Allebeck P., Cullberg J., et al. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiat 1999, 56:234-240.
14. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiat 1998, 155:1661-1670.
15. Garay P.A., McAllister A.K. Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Frontiers in Synaptic Neurosci 2010, 2:1-16.
16. Winter C., Djodari-Irani A., Sohr R., et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009, 12:513-524.
17. Vuillermot S., Weber L., Feldon J., et al. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
18. Cardenas I., Means R.E., Aldo P., et al. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol 2010, 185:1248-1257.
19. Deng M.Y., Lam S., Meyer U., et al. Frontal-subcortical protein expression following prenatal exposure to maternal inflammation. PLoS ONE 2011, 6:e16638.
20. Miller BJ, Culpepper N, Rapoport MH, et al. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiat, in press.
21. Connor C.M., Dincer A., Straubhaar J., et al. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr Res 2012, 140:175-184.
22. Garay PA, Hsiao EY, Patterson PH, et al. Maternal immune activation causes age-and region-specific changes in brain cytokines in offspring throughout development. Brain Behav Immun, in press.
23. Miller B.J., Buckley P., Seabolt W., et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiat 2011, 70:663-671.
24. Debnath M., Doyle K.M., Langan C., et al. Recent advances in psychoneuroimmunology: inflammation in psychiatric disorders. Trans Neurosci 2011, 2:121-137.
25. Baune B.T., Konrad C., Grotegerd D., et al. Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain. J Neuroinflammation 2012, 9:125.
26. Marsland A.L., Petersen K.L., Sathanoori R., et al. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med 2006, 68:895-903.
27. Marsland A.L., Gianaros P.J., Abramowitch S.M., et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiat 2008, 64:484-490.
28. Tonelli L.F., Postolache T.T. Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurological Res 2005, 27:679-684.
29. Baune B.T., Camara M.L., Eyre H., et al. Tumor necrosis factor-alpha mediated mechanisms of cognitive dysfunction. Trans Neurosci 2012, 3:263-277.
30. van Os J., Kapur S. Schizophrenia Lancet 2009, 374:635-645.
31. Garver D.L., Tamas R.L., Holcomb J.A. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 2003, 28:1515-1520.
32. García-Miss Mdel R., Pérez-Mutul J., López-Canul B., et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiat Res 2010, 44:441-446.
33. Beumer W, Drexhage RC, De Wit H, et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology, in press.
34. Czerski P.M., Rybakowski F., Kapelski P., et al. Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008, 57:88-94.
35. Paul-Samojdeny M., Kowalczyk M., Suchanek R., et al. Functional polymorphism in the Interleukin-6 and Interleukin-10 genes in patients with paranoid schizophrenia - a case-control study. J Mol Neurosci 2010, 42:112-119.
36. Naz M., Riaz M., Saleem M. Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 2011, 38:4709-4714.
37. Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun, in press.
38. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiat, in press.
39. Zakharyan R., Petrek M., Arakelyan A., et al. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012, 80:136-142.
40. Zhong H.J., Peng L., Zhu Y.S., et al. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011, 28:427-431.
41. Watanabe Y., Muratake T., Kaneko N., et al. No association between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiat Res 2007, 153:1-6.
42. Pae C.U., Drago A., Chiesa A., et al. Association analysis of the Tumor necrosis factor gene polymorphisms (TNFA 238 and 302) in the development of schizophrenia: impact on the antipsychotic treatment response. Gene Ther Mol Biol 2009, 13:152-157.
43. Duan S., Xu Y., Chen W., et al. No association between the promoter variants of tumor necrosis factor alpha (TNF-α) and schizophrenia in Chinese Han population. Neurosci Lett 2004, 366:139-143.
44. Hoffmann S.C., Stanley E.M., Cox E.D., et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002, 2:560-567.
45. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders, patient edition (SCID-P), version 2. New York: Biometrics Research; 1996.
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV), Washington, DC; 1994.
47. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011, 25:181-213.
48. Jia P., Wang L., Meltzer H.Y., et al. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 2010, 122:38-42.
49. Sasayama D., Wakabayashi C., Hori H., et al. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiat Res 2011, 45:1439-1444.
50. Singh B., Bera N.K., Nayak C.R., et al. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47:1-5.
51. Francesconi L.P., Ceresér K.M., Mascarenhas R., et al. Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 2011, 502:143-146.
52. Dean B, Gibbons AS, Tawadros N, et al. Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders. Mol Psychiat, in press.
53. Morar B., Schwab S.G., Albus M., et al. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiat Genet 2007, 144B:318-324.
54. Sacchetti E., Bocchio-Chiavetto L., Valsecchi P., et al. G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun 2007, 21:450-457.
55. Saviouk V., Chow E.W.C., Bassett A.S., Brzustowicz L.M. Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiat 2005, 10:375-383.